CombinAble.AI

CoombinAble.AI is an emerging Biotech start-up operating within the AION Labs (https://aionlabs.com) located in Rehovot, Israel. AION Labs is a first-of-its-kind alliance of global pharma and technology leaders and investors - AstraZeneca, Merck, Pfizer, Teva, the Israel Biotech Fund and Amazon Web Services (AWS) powered by BioMed X and with support from the Israel Innovation Authority that have come together with one clear mission: to create and adopt gateway AI and computational technologies that will transform the process of drug discovery and development for the betterment of human health. At Combinable, we are committed to change the antibody optimization process by consolidating it into a single in-silico solution. The traditional trial-and-error approach often struggles to balance multiple critical antibody characteristics simultaneously. Our approach involves a merging cutting-edge AI technology with state-of-the-art computational methods for biomolecule simulations. We aim to markedly reduce both the time and cost associated with the discovery process, enabling the design of innovative, safe, and highly effective biological therapeutics spanning a wide range of diseases.